Geneva, March 20 -- International Clinical Trials Registry received information related to the study (NCT07450859) titled 'A Study of BT5528 in Patients With Metastatic Pancreatic Ductal Adenocarcinoma (PDAC)' on Feb. 26.

Study Type: Interventional

Study Design: Allocation: N/A. Intervention model: Single Group Assignment. Primary purpose: Treatment. Masking: None (Open Label).

Primary Sponsor: BicycleTx Limited

Condition: Pancreatic Ductal Adenocarcinoma (PDAC)

Intervention: Drug: BT5528

Recruitment Status: Recruiting

Phase: Phase 2

Date of First Enrollment: March 2026

Target Sample Size: 39

Countries of Recruitment: United States

To know more, visit https://clinicaltrials.gov/study/NCT07450859

Published by HT Digital ...